DE60222031T2 - Stereoselektives verfahren zur herstellung von nukleosidderivaten - Google Patents

Stereoselektives verfahren zur herstellung von nukleosidderivaten Download PDF

Info

Publication number
DE60222031T2
DE60222031T2 DE60222031T DE60222031T DE60222031T2 DE 60222031 T2 DE60222031 T2 DE 60222031T2 DE 60222031 T DE60222031 T DE 60222031T DE 60222031 T DE60222031 T DE 60222031T DE 60222031 T2 DE60222031 T2 DE 60222031T2
Authority
DE
Germany
Prior art keywords
cis
formula
trans
alkyl
coupling
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60222031T
Other languages
German (de)
English (en)
Other versions
DE60222031D1 (de
Inventor
Qing Laval Yu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shire Canada Inc
Original Assignee
Shire BioChem Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire BioChem Inc filed Critical Shire BioChem Inc
Publication of DE60222031D1 publication Critical patent/DE60222031D1/de
Application granted granted Critical
Publication of DE60222031T2 publication Critical patent/DE60222031T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D327/00Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D327/02Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms one oxygen atom and one sulfur atom
    • C07D327/04Five-membered rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D411/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/04Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Saccharide Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
DE60222031T 2001-06-15 2002-06-14 Stereoselektives verfahren zur herstellung von nukleosidderivaten Expired - Lifetime DE60222031T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29807901P 2001-06-15 2001-06-15
US298079P 2001-06-15

Publications (2)

Publication Number Publication Date
DE60222031D1 DE60222031D1 (de) 2007-10-04
DE60222031T2 true DE60222031T2 (de) 2008-05-21

Family

ID=23148927

Family Applications (2)

Application Number Title Priority Date Filing Date
DE60222031T Expired - Lifetime DE60222031T2 (de) 2001-06-15 2002-06-14 Stereoselektives verfahren zur herstellung von nukleosidderivaten
DE60208202T Expired - Lifetime DE60208202T2 (de) 2001-06-15 2002-06-14 Stereoselektives verfahren zur herstellung von nukleosidanaloga

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE60208202T Expired - Lifetime DE60208202T2 (de) 2001-06-15 2002-06-14 Stereoselektives verfahren zur herstellung von nukleosidanaloga

Country Status (28)

Country Link
US (2) US7109334B2 (enExample)
EP (2) EP1632490B1 (enExample)
JP (1) JP4542776B2 (enExample)
KR (1) KR100832617B1 (enExample)
CN (1) CN1297553C (enExample)
AP (1) AP1559A (enExample)
AT (2) ATE313542T1 (enExample)
AU (2) AU2002344862C1 (enExample)
BR (2) BR0210444A (enExample)
CA (1) CA2449338C (enExample)
CO (1) CO5550497A2 (enExample)
CY (1) CY1107805T1 (enExample)
DE (2) DE60222031T2 (enExample)
DK (2) DK1632490T3 (enExample)
EA (1) EA006372B1 (enExample)
ES (2) ES2293445T3 (enExample)
HR (1) HRP20031021B1 (enExample)
IL (2) IL159139A0 (enExample)
MX (1) MXPA03011627A (enExample)
NO (1) NO326135B1 (enExample)
NZ (1) NZ529906A (enExample)
OA (1) OA12628A (enExample)
PL (2) PL215267B1 (enExample)
PT (1) PT1632490E (enExample)
RS (1) RS50868B (enExample)
SI (2) SI1406896T1 (enExample)
WO (1) WO2002102796A1 (enExample)
ZA (1) ZA200309307B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7501514B1 (en) 2003-10-15 2009-03-10 Shire Biochem, Inc. Enantiomeric resolution of 2-substituted 4-substituted 1,3-oxathiolanes nucleosides
JP4653966B2 (ja) * 2004-04-19 2011-03-16 ダイセル化学工業株式会社 2−ベンゾイルオキシアセトアルデヒド誘導体の製造法
WO2009039582A1 (en) * 2007-09-28 2009-04-02 Avexa Limited A process for chiral resolution of 2-substituted 4-substituted 1,3-oxathiolanes
US20130165350A1 (en) * 2011-12-22 2013-06-27 Affymetrix, Inc. Surface linkers for array synthesis

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR840001591A (ko) * 1981-09-29 1984-05-07 구라바야시 이꾸시로 당케탈류의 제조방법
US5587480A (en) * 1990-11-13 1996-12-24 Biochem Pharma, Inc. Substituted 1,3-oxathiolanes and substituted 1,3-dithiolanes with antiviral properties
ATE143016T1 (de) * 1990-11-13 1996-10-15 Iaf Biochem Int Substituierte 1,3-oxathiolane mit antiviralen eigenschaften
US5532349A (en) * 1993-07-20 1996-07-02 Mitsui Toatsu Chemicals, Inc. Process for producing 1-(2'-deoxy-β-D-erythro-pentofuranosyl)-5-trifluoromethyluracil derivatives
ES2232169T3 (es) * 1998-08-12 2005-05-16 Gilead Sciences, Inc. Procedimiento de fabricacion de nucleosidos de 1,3-oxatiolano.

Also Published As

Publication number Publication date
NZ529906A (en) 2006-03-31
DE60208202T2 (de) 2006-08-17
DK1632490T3 (da) 2008-01-28
DE60222031D1 (de) 2007-10-04
SI1406896T1 (sl) 2006-04-30
AU2002344862B2 (en) 2008-05-01
EA200400042A1 (ru) 2004-06-24
KR100832617B1 (ko) 2008-05-27
HK1070652A1 (en) 2005-06-24
KR20040017233A (ko) 2004-02-26
CO5550497A2 (es) 2005-08-31
ATE370945T1 (de) 2007-09-15
JP2004535428A (ja) 2004-11-25
HRP20031021A2 (en) 2004-06-30
WO2002102796A8 (en) 2003-09-18
PL218777B1 (pl) 2015-01-30
WO2002102796A1 (en) 2002-12-27
PL366907A1 (en) 2005-02-07
US20060183899A1 (en) 2006-08-17
HRP20031021B1 (hr) 2007-09-30
IL159139A (en) 2010-04-15
BR0210444A (pt) 2004-08-17
NO20035556D0 (no) 2003-12-12
BRPI0210444B1 (pt) 2017-06-20
NO326135B1 (no) 2008-10-06
JP4542776B2 (ja) 2010-09-15
CN1297553C (zh) 2007-01-31
AP1559A (en) 2006-01-24
YU97503A (sh) 2006-05-25
CA2449338A1 (en) 2002-12-27
SI1632490T1 (sl) 2008-02-29
PT1632490E (pt) 2007-11-07
DE60208202D1 (de) 2006-01-26
EP1632490B1 (en) 2007-08-22
EP1406896A1 (en) 2004-04-14
ZA200309307B (en) 2005-02-23
EP1406896B1 (en) 2005-12-21
PL215267B1 (pl) 2013-11-29
US7109334B2 (en) 2006-09-19
US7230100B2 (en) 2007-06-12
ES2293445T3 (es) 2008-03-16
ATE313542T1 (de) 2006-01-15
DK1406896T3 (da) 2006-05-08
US20030135048A1 (en) 2003-07-17
CA2449338C (en) 2012-02-07
OA12628A (en) 2006-06-13
CN1543463A (zh) 2004-11-03
EP1406896B8 (en) 2006-11-15
MXPA03011627A (es) 2005-03-07
IL159139A0 (en) 2004-06-01
AU2008203443B2 (en) 2011-06-16
EP1632490A1 (en) 2006-03-08
EA006372B1 (ru) 2005-12-29
PL401835A1 (pl) 2013-02-18
CY1107805T1 (el) 2013-06-19
RS50868B (sr) 2010-08-31
AU2002344862C1 (en) 2009-02-19
AU2008203443A1 (en) 2008-08-21
ES2254695T3 (es) 2006-06-16

Similar Documents

Publication Publication Date Title
DE69233014T2 (de) Verfahren für die herstellung von antiviralen substituierten 1, 3-oxathiolanen
DE69510347T2 (de) Verfahren zu diastereoselektiven herstellung von nucleosid analoga
DE69921829T2 (de) Verfahren zur herstellung von 1,3-oxathiolannukleoside
JPH05186463A (ja) ヌクレオシドのジアステレオ選択的合成法
DE60222031T2 (de) Stereoselektives verfahren zur herstellung von nukleosidderivaten
US5763606A (en) Stereoselective synthesis of nucleoside analogues using bicyclic intermediate
AU2002344862A1 (en) Stereoselective method for the preparation of nucleoside analogues
HK1008673B (en) Stereoselective synthesis of nucleoside analogues using bicyclic intermediate

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: SHIRE BIOCHEM INC., VILLE ST-LAURENT, QUEBEC, CA

8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: SHIRE CANADA INC., VILLE ST.-LAURENT, QUEBEC, CA